Darunavir (Prezista): A HIV-1 Protease Inhibitor for Treatment of Multidrug-Resistant HIV

Modern Drug Synthesis

Volumn , Issue , 2010, Pages 29-44

  Ghosh, Arun K ^a   Martyr, Cuthbert D ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Biochemical events; Darunavir; Multidrug resistant; Protease inhibitors; Reverse transcriptase

Indexed keywords

EID: 79954601629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470768594.ch3     Document Type: Chapter

References (41)

1. UNAIDS/WHO. "Report on Annual AIDS Epidemic Update, December 2008."www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Globalreport.asp, accessed August 2009.
2. Coffin, J.; Hughes, S.; Varmus, H. Retroviruses, New York: Cold Spring Harbor Laboratory Press, 1997.
3. Clercq, E. D. J. Med. Chem. 2005, 48, 1297-1313.
4. Antiviral Agents Bull. 1995, 8, 353-55.
5. Staszewski, S.; Morales-Ramirez, J.; Tashima, K. T.; Rachlis, A.; Skiest, D.; Stanford, J.; Stryker, R.; Johnson, P.; Labriola, D. F.; Farina, D.; Manion, D. J.; Ruiz, N. M. (for the study 006 Team), N. Engl. J. Med. 1999, 341, 1865-1873.
6. Wainberg, M. A.; Friedland, G. JAMA 1998, 279, 1977-1983.
7. FDA. "FDA Approves New HIV Treatment for Patients Who Do not Respond to Existing Drugs, June 2006." www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2006/ucml 08676.htm, accessed April 2010.
8. On October 21, 2008, FDA granted traditional approval to Prezista (darunavir), co-administered with ritonavir and with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-experienced adult patients. In addition to the traditional approval, a new dosing regimen for treatment-naive patients was approved.
9. Ghosh, A. K.; Chapsal, B. D.; Weber, I. T.; Mitsuya, H. Ace. Chem. Res. 2008, 41, 78-86.
10. Kovalevsky, A. Y.; Tie, Y.; Liu, F.; Boross, P. I.; Wang, Y. F.; Leshchenko, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. J. Med. Chem. 2006, 49, 1379-1387.
11. Ghosh, A. K.; Sridhar, P. R.; Kumaragurubaran, N.; Koh, Y.; Weber, I. T.; Mitsuya, H. ChemMedChem 2006,1, 939-950.
12. (a) Miller, J. F.; Andrews, C. W.; Brieger, ML; Furfine, E. S.; Hale, M. R.; Hanlon, M. H.; Hazen, R. J.; Kaldor, I.; et al. Bioorg. Med. Chem. Lett. 2006, 16, 1788-1794.
13. (b) Ford, S. L.; Reddy, S. S.; Anderson, M. T.; Murray, S. C; Fernandez, P.; Stein, D. S.; Johnson, M. A. Antimicrob. Agents Chemother. 2006, 50,2201-2206.
14. GSK. "Corporate Responsibility Report 2006." www.gsk.com/responsibility/downloads/CR-Report-2006.pdf, accessed April 2010.
15. Cihlar, T.; He, G.-X.; Liu, X.; Chen, J. M.; Hatada, M.; Swaminathan, S.; McDermott, M. J.; Yang, Z.-Y.; et al. J. Mol. Biol. 2006, 363, 635-647.
16. Callebaut, C; Stray, K.; Tsai, L.; Xu, L.; Lee, W.; Cihlar, T. Paper presented at 16th International HIV Drug Resistance Workshop, June 12-16,2007, Barbados.
17. Surleraux, D. L. N. G.; de Kock, B. A.; Verschueren, W. G.; Pille, G. M. E.; Maes, L. J. R.; Peeters, A.; Vendeville, S.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M-P.; King, N. M.; Jeyabalan, M. P.; Schiffer, C. A.; Wigernick, P. B. T. P. J. Med. Chem. 2005, 48, 1965-1973.
18. (a) Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; et al. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
19. (b) De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M.-P. Antimicrob. Agents Chemother. 2005,49,2314-2321.
20. Koh, Y.; Matsumi, S.; Das, D.; Amano, M.; Davis, D. A.; Li, J. F.; Leschenko, S.; Baldridge, A.; et al. J. Biol Chem. 2007, 282, 28709-28720.
21. Fujimoto, H.; Higuchi, M.; Watanabe, H.; Koh, Y.; Ghosh, A. K.; et al. Biol Pharm. Bull 2009, 32, 1588-1593.
22. Rittweger, M.; Arasteh, K.; et al. Clinical Pharmacokin. 2007, 46, 739-56.
23. Benet, L. Z.; Izumi, T.; Zhang, Y.; Silverman, J. A.; Wacher, V. J. J. Controlled Release 1999, 62,25-31.
24. Cooper, C. L.; van Heeswijk, R. P.; Gallicano, K.; Cameron, D. W. Clin. Infect. Dis. 2003, 36, 1585-1592.
25. Vermeir, M.; Lachau-Durand, S; Mannens, G.; Cuyckens, F.; van Hoof, B.; Raoof, A. Drug Metab. Dispos. 2009, 37, 809-820.
26. Molina, J.-M.; Cohen, C; Katlama, C; Grinsztejn, B.; Timerman, A.; Pedro, R.; et al. Abstract P4, Paper presented at the 12th Annual BHIVA, March 29-April 1,2006, Brighton, UK.
27. Hazen, R.; Harvey, R.; Ferris, R.; Craig, C; Yates, P.; Griffin, P.; Miller, J.; Laldor, L; et al. Antimicrob. Agents Chemother. 2007, 51, 3147-3154.
28. Label information for PREZISTA (Darunavir Ethanolate). www.accessdata.fda.gov/scripts/cder/dmgsatfda/index.cfm?fuseaction=Search.L abelApprovalHistory, accessed January 2010.
29. McKeage, K.; Perry, C. M.; Keam, S. J. Drugs 2009, 69, 477-503.
30. Ghosh, A. K.; Kincaid, J. F.; Walters, D. E.; Chen, Y.; Chaudhuri, N. C; Thompson, W. J.; Culberson, C; Fitzgerald, P. M. D.; et al. J. Med. Chem. 1996, 39, 3278-3290.
31. Ghosh, A. K.; Chen, Y. Tetrahedron Lett. 1995, 36, 505-508.
32. Ghosh, A. K.; Leshchenko, S.; Noetzel, M. J. Org. Chem. 2004, 69, 7822-7829.
33. Quaedflieg, P. J. L. M.; Kesteleyn, B. R. R.; Wigerinck, P. B. T. P.; Goyvaerts, N. M. F.; Vijn, R. J.; Liebregts, C. S. M.; Kooistra, J. H. M. H.; Cusan, C. Org. Lett. 2005, 7, 5917-5920.
34. (a) Yu, R. H.; Polniaszek, R. P.; Becker, M. W.; Cook, C. M.; Yu, L. H. L. Org. Proc. Res. Dev. 2007, 11, 972-980.
35. (b) Black, D. M.; Davis, R.; Doan, B. D.; Lovelace, T. C; Millar, A.; Toczko, J. F.; Xie, S. P. Tetrahedron Asym. 2008, 79,2015-2019.
36. Lemaire, S. F. E.; Horvath, A.; Aelterman, W. A. A.; Rammeloo, T. J. L. PCT/EP2007/ 062119, Nov. 9, 2007.
37. Ghosh, A. K; Kawahama, R. Tetrahedron Lett. 1999, 40, 1083-1086.
38. Doan, B. D.; Davis, R. D.; Lovelace, T. C. PCT/US02/29315 and WO 03/024974 A2, March 27, 2003.
39. Ghosh, A. K.; Li, J.; Perali, R. S. Synthesis 2006, 3015-3018.
40. Ghosh, A. K.; Thompson, W. J.; Holloway, M. K.; McKee, S. P.; Duong, T. T.; Lee, H. Y.; Munson, P. M; Smith, A. M.; Wai, J. M.; Darke, P. L.; et al. J. Med. Chem. 1993, 36, 2300-2310.
41. Ghosh, A. K.; Bilcer, G.; Schlitz, G. Synthesis 2001, 2203-2229.